Publications by authors named "Braden Probst"
Article Synopsis
- Uterine serous carcinomas (USC) make up 10% of uterine cancers but cause 40% of related deaths, highlighting the need for better molecular profiling for treatment.
- A study of 53 USC patients analyzed genomic instability scores (GIS), tumor mutational burden (TMB), and tumor-infiltrating lymphocytes (TILs) to understand survival outcomes.
- Results indicated that a higher TMB correlates with improved survival rates, while the GIS did not show a similar association; increased TILs were related to higher GIS scores.
Purpose: Polygenic risk scores (PRSs) for breast cancer (BC) risk stratification have been developed primarily in women of European ancestry. Their application to women of non-European ancestry has lagged because of the lack of a formal approach to incorporate genetic ancestry and ancestry-dependent variant frequencies and effect sizes. Here, we propose a multiple-ancestry PRS (MA-PRS) that addresses these issues and may be useful in the development of equitable PRSs across other cancers and common diseases.
View Article and Find Full Text PDFArticle Synopsis
- The EndoPredict assay, previously validated for post-menopausal women with ER+, HER2- breast cancer, was tested for its effectiveness in predicting outcomes in pre-menopausal women with the same cancer type.
- A study involving 385 pre-menopausal women found that both the EP molecular score and the EPclin score were significant predictors of distant recurrence-free survival (DRFS) over a 9.7-year follow-up, with low-risk patients showing much better survival rates.
- These results suggest that pre-menopausal women classified as low-risk by the EPclin score can safely be treated with endocrine therapy alone, potentially avoiding the need for chemotherapy.
Purpose: Breast cancer risks for and pathogenic variant (PV) carriers are modified by an 86-single nucleotide polymorphism polygenic risk score (PRS) and individual clinical factors. Here, we describe comprehensive risk prediction models for women of European ancestry combining PV status, PRS, and individual clinical variables.
Materials And Methods: This study included deidentified clinical records from 358,095 women of European ancestry who received testing with a multigene panel (September 2013 to November 2019).
Background: The IBIS/Tyrer-Cuzick model is used clinically to guide breast cancer screening and prevention, but was developed primarily in non-Hispanic White women. Little is known about its long-term performance in a racially/ethnically diverse population.
Methods: The Women's Health Initiative study enrolled postmenopausal women from 1993-1998.